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Abstract	25	
Glycine	encephalopathy	(GE)	or	Non-Ketotic	Hyperglycinemia	(NKH),	is	a	rare	recessive	genetic	26	
disease	caused	by	defective	glycine	cleavage	and	characterized	by	an	increased	accumulation	of	27	
glycine	in	all	tissues.	Here,	based	on	new	case-reports	of	GLDC	loss-of-function	mutations	in	GE	28	
patients,	 we	 aimed	 at	 generating	 a	 zebrafish	 model	 of	 severe	 GE	 in	 order	 to	 unravel	 the	29	
molecular	 substratum	 of	 the	 disease.	 Using	 CRISPR/CAS9,	 we	 knocked-out	 gldc	 gene	 and	30	
showed	 that	 -/-	 fish	 recapitulate	 GE	 on	 a	 molecular	 level	 and	 depict	 a	 motor	 phenotype	31	
reminiscent	of	severe	GE	symptoms.	The	molecular	characterization	of	gldc	-/-	mutants	showed	32	
a	broad	metabolic	disturbance	affecting	amino	acids	and	neurotransmitters	other	than	glycine,	33	
with	lactic	acidosis	at	stages	preceding	death.	Although	a	transient	imbalance	was	found	in	cell	34	
proliferation	in	the	brain	of	gldc	-/-,	the	main	brain	networks	are	not	affected	thus	suggesting	35	
that	 GE	 pathogenicity	 is	 mainly	 due	 to	 metabolic	 defects.	We	 confirmed	 that	 the	 gldc	 -/-	36	
hypotonic	phenotype	is	due	to	NMDA	and	glycine	receptors	overactivation,	and	demonstrated	37	
that	gldc-/-	 larvae	depict	an	exacerbated	hyperglycinemia	at	 these	synapses.	Remarkably,	we	38	
were	 able	 to	 rescue	 the	 motor	 dysfunction	 of	 gldc-/-	 larve	 by	 counterbalancing	39	
pharmacologically	or	genetically	the	level	of	glycine	at	the	synapse.	40	
	41	
42	
Introduction	43	
Glycine	encephalopathy	(GE),	also	known	as	nonketotic	hyperglycinemia	(MIM	605899),	44	
is	a	rare	genetic	defect	in	glycine	metabolism	characterized	by	a	considerable	accumulation	of	45	
glycine	 in	 all	 tissues,	 especially	 in	 the	 central	 nervous	 system	 (1-4).	 GE	 has	 an	 autosomal	46	
recessive	 inheritance	pattern	and	 is	 classically	 caused	by	mutations	 in	proteins	of	 the	glycine	47	
cleavage	 system	 composed	 of	 a	 glycine	 decarboxylase	 (GLDC),	 an	 aminomethyltransferase	48	
(AMT),	a	hydrogen	carrier	protein	(GCSH),	and	a	dihydrolipoamide	dehydrogenase	(DLD)	(4,	5).	49	
All	four	subunits	are	encoded	by	distinct	genes	and	GLDC	is	mutated	in	72%	of	the	GE	cases(2).	50	
The	symptoms	of	GE	are	commonly	 first	observed	during	 the	neonatal	period	and	are	51	
very	heterogeneous	among	the	patients,	depending	on	the	pathogenicity	of	the	mutation	(5,	6).	52	
In	severe	GE,	the	neonates	present	severe	hypotonia,	myoclonic	jerks,	lethargy	and	apnea	due	53	
to	respiratory	depression,	which	often	causes	death	within	the	first	week	of	 life.	The	patients	54	
with	 severe	 GE	 surviving	 the	 neonatal	 period	 make	 no	 developmental	 progress	 and	 show	55	
spasticity,	intractable	seizures	and	hypotonia.	Individuals	with	attenuated	GE	often	survive	the	56	
neonatal	 period	 but	 show	 treatable	 seizures,	 spasticity,	 chorea	 and	 variable	 developmental	57	
delay	that	often	leads	to	intellectual	disability	(5,	6).		58	
The	 treatments	available	 for	GE	patients	are	primarily	used	to	alleviate	 the	symptoms	59	
but	 do	 not	 resolve	 the	 underlying	 metabolic	 defects.	 Indeed,	 dextromethorphan,	 an	 NMDA	60	
receptor	antagonist,	is	used	to	diminish	the	seizures,	and	sodium	benzoate	helps	reduce	glycine	61	
levels	by	elimination	through	the	urine.	Unfortunately,	even	when	combined	these	treatments	62	
fail	 to	 improve	the	outcome	of	many	GE	patients	 (6).	However,	although	the	clinical	research	63	
done	on	human	patients	has	helped	identify	the	genetic	causes	of	the	disease	and	characterize	64	
the	spectrum	of	symptoms,	it	has	not	elucidated	the	molecular	basis	of	GE.		65	
A	 few	 research	 efforts	 have	 been	 made	 to	 model	 the	 disease.	 In	 mouse,	 a	 loss-of-66	
function	gene-trap	allele	and	a	dominant-negative	model	of	gldc	that	show	features	of	GE,	such	67	
as	 early	 lethality,	 increased	 glycine,	 and	 hydrocephalus,	 were	 generated	 (7,	 8).	 	 A	 zebrafish	68	
model	was	described	 in	which	the	hyperglycinemia	 is	restricted	to	the	brain,	but	 it	cannot	be	69	
used	to	study	the	classical	 form	of	the	disease	(9).	 	These	models	help	understand	aspects	of	70	
GE,	but	did	not	focus	on	characterizing	the	pathogenic	mechanisms	underlying	the	disease.	As	a	71	
result,	this	highlights	the	necessity	of	generating	an	accurate	and	reliable	animal	model	of	GE,	72	
more	amenable	to	metabolic	analyses	and	high	throughput	drug	screens.		73	
Here	we	report	two	new	cases	of	GE	patients	carrying	loss-of-function	mutations	in	one	74	
or	both	GLDC	alleles.	At	this	juncture,	we	generated	a	zebrafish	model	of	GE	(gldc-/-)	depicting	75	
high	level	of	glycine	and	displaying	motor	abnormalities	and	premature	death,	thus	resembling	76	
the	 fatal	 outcome	 of	 severe	 forms	 of	 GE.	 Next,	 we	 performed	 unbiased	 high-throughput	77	
proteomics	and	 transcriptomics	analysis	 and	 showed	 that	gldc	 loss-of-function	 induces	broad	78	
metabolic	defects.	We	also	confirmed	synaptic	glycine-signaling	abnormalities	and	remarkably	79	
were	 able	 to	 rescue	 the	 hypotonic	 phenotype	 of	 gldc	 -/-	 larvae	 by	 counterbalancing	 the	80	
hyperglycinemia	at	the	synapse.	81	
	82	
Results	83	
Two	case-reports	of	GE	associated	with	mono-allelic	or	bi-allelic	LOF-mutations	in	GLDC	84	
The	first	patient	we	examined	was	a	deceased	female	infant	born	at	39	week	gestational	85	
age.	Pregnancy	was	uncomplicated	and	she	was	delivered	vaginally	with	Apgar	 scores	of	8	at	86	
one	minute	and	9	at	five	minutes.		She	was	discharged	from	the	nursery	at	2	days	of	life.	At	4	87	
days	 of	 life	 she	 became	 lethargic	 with	 poor	 feeding	 and	 was	 admitted	 again.	 	 Her	 physical	88	
examination	 was	 significant	 for	 respiratory	 failure	 requiring	 intubation,	 diffuse	 hypotonia,	89	
absent	deep	tendon	reflexes,	withdrawal	to	painful	stimuli,	rhythmic	hiccupping	and	myoclonic	90	
movements	of	the	right	upper	extremity.		MRI	on	day	4	of	life	revealed	a	small	but	completely	91	
formed	corpus	callosum	with	a	mild	delay	in	myelination	and	a	slightly	lower	volume	of	cerebral	92	
white	 matter.	 EEG	 revealed	 burst	 suppression	 pattern.	 	Her	 seizures	 were	 treated	 with	93	
phenobarbital	 and	 ativan,	 but	 were	 relatively	 refractory	 to	 medication.	 Additional	 testing	94	
revealed	 an	 elevated	plasma	 glycine	 level	 of	 125	umol/dL	 (0-57)	 and	 elevated	 glycine	CSF	of	95	
33.8	umol/dL	(0.2-2.0).	The	CSF/plasma	glycine	ratio	of	0.27	(pathognomonic	ratio	>0.08)	was	96	
diagnostic	of	GE	(or	nonketotic	hyperglycinemia).		Given	the	grave	prognosis	of	this	disease,	the	97	
infant’s	 family	 decided	 to	 withdraw	life-sustaining	 treatment	on	 day	 10	 of	 life.	 Newborn	98	
screening	was	negative	and	chromosomal	studies	were	pending	at	the	time	of	death.	Molecular	99	
testing	 revealed	 two	 variants	 in	 the	GLCD	 gene:	 c.1153	 C>T	 (p.Q385X)	 and	 c.941	 ins16nt	 fs	100	
(Figure	1).		101	
The	 second	 patient	 was	 a	 50-year-old	 gentleman	 who	 presented	 initially	 to	 adult	102	
neurology	for	a	movement	disorder.	He	was	non-verbal,	had	limited	facial	expression,	drooled,	103	
and	had	a	constant	tremor.		He	was	unable	to	walk	unassisted	and	required	caretakers	to	assist	104	
with	personal	tasks	such	as	feeding	and	toileting.	He	had	a	history	of	myoclonic	jerks	and	was	105	
treated	with	 valproic	 acid.	 Clinical	 evaluation	 identified	 a	mild	 elevation	 of	 glycine.	 	 Genetic	106	
testing	 identified	 two	 variants	 in	 GLCD	 c.1054delA(p.Thr352fster65)	 and	107	
c.1705C>T(p.Ala569Thr)	(NM00170.2,	Figure	1)	and	paternal	testing	supported	that	the	variants	108	
were	in	trans.		Although	the	first	allele	carrying	a	nonsense	mutation	is	pathogenic,	the	second	109	
one	with	a	missense	mutation	has	been	 recently	 reported	as	non	pathogenic	with	a	 residual	110	
enzymatic	 activity	 of	 about	 70%	 (10).	 After	 the	 diagnosis,	 valproic	 acid	 was	 promptly	111	
discontinued	 and	 the	 patient	 was	 started	 on	 dextromethoraphan	 and	 sodium	 benzoate.		112	
Glycine	 levels	 fell	 into	the	normal	range	and	the	patient	had	 improved	mobility,	resolution	of	113	
constant	tremors,	stopped	drooling,	and	was	able	to	feed	himself.	However,	his	general	quality	114	
of	life	was	still	severely	impaired	since	he	needs	daily	assistance.		115	
These	two	cases	demonstrate	 the	clinical	heterogeneity	of	GE	and	are	consistent	with	116	
previous	study	linking	the	severity	of	the	disease	with	the	residual	GLDC	enzymatic	activity	of	117	
different	missense	mutations	(11).	118	
	119	
Zebrafish	gldc	is	expressed	in	the	CNS	and	its	loss-of-function	induces	glycine	accumulation		120	
We	started	by	examining	the	gldc	sequence	and	its	expression	in	zebrafish	embryos.	In	contrast	121	
to	the	common	gene	duplication	in	teleost	fish,	a	single	copy	of	the	gldc	gene	can	be	found	in	122	
the	zebrafish	genome	(ENSDAR00000035120)	and	it	shows	more	than	60%	overall	amino	acid	123	
identity	 with	 the	 human	 protein.	 We	 also	 assessed	 the	 expression	 pattern	 of	 gldc	 uring	124	
zebrafish	development	by	 in	 situ	hybridization	 from	8	hours	post-fertilization	 (hpf)	 to	42	hpf.	125	
Gldc	is	broadly	expressed	in	the	nervous	system	until	32	hpf,	and	at	42	hpf	its	expression	is	in	126	
specific	 brain	 regions	 (Figure	 2A).	 Interestingly,	 we	 observed	 that	 the	 expression	 become	127	
restricted	to	the	midbrain/hindbrain	boundary	and	the	commissural	regions	of	the	brain	from	3	128	
dpf.	From	4	dpf,	gldc	transcript	starts	to	be	strongly	expressed	in	the	liver,	the	intestine	and	the	129	
gut.	This	expression	persists	at	5	and	6	dpf	with	only	a	weak	expression	in	the	brain.	130	
The	 significant	 level	 of	 identity	 between	 human	 and	 zebrafish	 GLDC	 and	 its	 strong	131	
expression	in	the	embryonic	CNS	suggest	a	robust	evolutionary	conservation	of	GLDC	function,	132	
thus	supporting	the	pertinence	of	a	gldc	knock-out	zebrafish	to	model	the	human	disease.		133	
In	 designing	 gRNAs	 for	 the	 CRISPR/CAS9-mediated	 mutagenesis,	 we	 targeted	 the	134	
beginning	 of	 the	 glycine	 cleavage	 domain	with	 the	 aim	 of	 reproducing	 a	 pathogenic	 loss-of-135	
function	mutation.	We	selected	a	founder	transmitting	a	5	nucleotide	deletion	and	3	nucleotide	136	
mismatches	early	in	the	glycine	cleavage	domain,	creating	a	stop	codon	at	the	189th	amino	acid	137	
(Figure	2B-C).	Using	the	high-resolution	melting	(HRM)	analysis	(12),	we	could	easily	identify	all	138	
three	 genotypes	 (+/+,	 -/+,	 	 -/-)	 (Figure	 2B).	 We	 confirmed	 gldc	 knock-out	 by	 RT-qPCR	 and	139	
showed	that	-/-	embryos	have	reduced	levels	of	gldc	expression	compared	to	their	siblings,	as	140	
seen	in	patients	(13).		More	importantly,	Liquid	Chromatography	–	Mass	Spectrometry	(LC-MS)	141	
analysis	 of	 glycine	 levels	 in	 whole	 7	 dpf	 larvae	 supported	 the	 loss-of-function	 nature	 of	 the	142	
mutation,	 since	 gldc	 -/-	 larvae	 display	 4	 times	more	 accumulated	 glycine	 than	 their	 siblings	143	
(Figure	2D).	Altogether,	these	results	show	that	our	newly	generated	gldc-KO	line	recapitulates	144	
the	main	molecular	hallmarks	of	GE.	145	
	146	
Gldc	-/-	larvae	die	prematurely	and	depict	GE-reminiscent	motor	phenotypes	147	
	 While	most	of	the	gldc	+/+	and	-/+	larvae	survived	for	the	first	10	days	post	fertilization,	148	
all	the	gldc	-/-	 larvae	died	between	7	and	9	dpf	(Figure	3A).	After	measuring	the	body	length,	149	
eye	size	and	 inter-eye	distance	of	-/-	 larvae	compared	to	their	siblings,	we	did	not	notice	any	150	
morphological	abnormalities	of	the	mutant	larvae	(Figure	3B).		However,	gldc	-/-	larvae	from	6	151	
dpf	depict	an	evident	hyperpigmentation,	which	 is	practical	 to	easily	separate	 them	from	the	152	
siblings	 (Figure	3C).	 This	hyperpigmentation	phenotype	 segregates	with	 the	mutant	alleles	of	153	
gldc	 through	 multiple	 generations	 of	 fish,	 thus	 suggesting	 that,	 although	 unexpected,	 it	 is	154	
specific	 to	gldc	 loss-of-function.	 Although	 no	major	morphological	 differences	was	 observed,	155	
we	performed	transverse	sections	of	different	regions	of	the	larval	brain	(forebrain,	midbrain,	156	
hindbrain	and	anterior	spinal	cord)	and	we	did	not	notice	any	obvious	morphological	difference	157	
between	gldc+/+	and	-/-	at	7	dpf	(Figure	3D).	158	
Since	the	GE	patients	show	early	motor	symptoms	such	as	hypotonia	and	lethargy,	we	159	
analyzed	the	larval	motor	function	of	the	gldc	mutants.	Spontaneous	coiling	is	the	first	motor	160	
output	in	zebrafish	embryos	occurring	between	17-21	hpf	and	consisting	of	frequent	un-evoked	161	
movements	of	the	tail	in	the	chorion	(14).	Analysis	of	this	motor	behavior	indicated	a	decrease	162	
in	coiling	frequency	of	gldc	-/-	embryos	compared	to	their	siblings	(1.46	±	0.31	n=14,	12.81	±	163	
2.73	n=11;	Figure	3E).	At	the	larval	stage,	we	assayed	the	swimming	activity	of	gldc	mutants	by	164	
recording	 the	 total	 distance	 swam	 over	 one	 hour	 and	 we	 noticed	 a	 reduction	 of	 swimming	165	
activity	in	gldc	-/-	larvae	at	7	dpf	(650.6mm	±	138.4	n=23,	1646mm	±	332.1	n=10;	Figure	3F).	Of	166	
note	is	that	this	reduced	swimming	behavior	starts	at	4	dpf	and	is	more	and	more	evident	with	167	
age.	168	
Hypotonia	and	lethargy	are	respectively	defined	as	a	state	of	low	muscle	tone	and	a	lack	169	
of	 vigor.	 Thus	 we	 tracked	 the	 path	 swam	 by	 gldc-/-	 larvae	 after	 applying	 a	 circular	 water	170	
current,	as	well	as	the	time	needed	to	immobilize	in	the	dish	(e.g.	stabilize	their	position).	While	171	
the	siblings	can	actively	swim	against	the	water	current	in	order	to	maintain	their	position,	gldc	172	
-/-	mutants	were	unable	to	fight	against	it	and	to	stabilize	their	position.	As	a	result,	they	were	173	
passively	 carried	 through	 the	 dish	 by	 the	water	 current	 in	 a	 lethargic	 and	 hypotonic	 fashion	174	
(Figure	 3G).	 Consistently,	 the	 time	 to	 stabilize	 their	 position	 after	 applying	 water	 current	 is	175	
significantly	 increased	 compared	 to	 their	 siblings	 (Figure	 3H).	 Furthermore,	 we	 noticed	 an	176	
anomaly	in	the	swimming	balance	of	gldc	-/-	larvae.	Indeed,	we	noticed	that	while	the	siblings	177	
are	 exploring	 their	 tank	 by	 swimming	 throughout	 it,	most	 of	 the	 gldc	 -/-	 larvae	 float	 at	 the	178	
surface,	 unable	 to	 explore	 their	 environment,	 indicating	 a	 swimming	 balance	 impairment	179	
(Figure	3I-J(Figure	3C).	 ).	Of	note	 is	 that	 although	 seizures	are	often	 reported	 in	GE	patients,	180	
electrophysiology	recordings	from	larval	brains	did	not	detect	any	electrical	discharge	in	gldc-/-	181	
(data	not	 shown).	Taken	 together	 these	 results	 show	that	 the	gldc	 -/-	mutants	display	motor	182	
phenotypes	reminiscent	of	GE	symptoms	in	human	patients,	such	as	early	lethality,	hypotonia,	183	
and	lethargy.		184	
	185	
Metabolomics	analysis	indicates	broad	metabolic	perturbations	in	gldc	-/-	larvae.	186	
	 After	 characterizing	 the	 disease-related	 phenotype	 of	 gldc	 -/-	 mutants,	 we	 sought	 to	187	
describe	the	molecular	mechanisms	involved	in	pathogenicity.	Since	glycine	acts	as	an	essential	188	
amino-acid	 as	 well	 as	 a	 neurotransmitter	 in	 the	 CNS,	 we	 conducted	 a	 broad	 assay	 of	189	
metabolites	 by	 LC-MS	 in	 order	 to	 titrate	 the	 level	 of	 all	 proteinogenic	 and	 the	 main	 non-190	
proteinogenic	amino	acids,	as	well	as	the	main	neurotransmitters.	Interestingly,	we	found	that	191	
extracts	 from	 gldc	 -/-	 larvae	 showed	 a	 significant	 increase	 in	 many	 amino	 acids	 other	 than	192	
glycine,	 such	 as	 sarcosine,	 proline,	 valine,	 cystathionine,	 leucine,	 and	 arginine	 (Figure	 4A).	193	
Moreover,	we	found	that	gldc	-/-	 larvae	depicted	a	significant	reduction	in	the	levels	of	GABA	194	
and	glutamate	compared	to	gldc	+/+	(Figure	4B)	whereas	dopamine	and	serotonin	levels	were	195	
not	significantly	affected.	Likewise,	this	suggests	that	gldc-KO	impairs	the	metabolism	of	amino-196	
acid/neurotransmitters	other	than	glycine.	We	next	sought	to	determine	 if	 these	changes	are	197	
the	result	of	an	accumulation	over	time	or	 if	 they	are	directly	 linked	with	GLDC-KO.	Thus,	we	198	
performed	the	same	LC-MS	analysis	at	2	dpf	and	noticed	that	only	sarcosine	and	glycine	were	199	
already	 significantly	 increases	 in	 gldc-/-	 (Figure	 S1).	 This	 suggest	 that	 the	 increased	 level	 of	200	
proline,	valine,	cystathionine,	 leucine	and	arginine	arise	with	time.	We	also	found	that	at	this	201	
early	stage,	methionine	is	significantly	decreases	in	mutant	embryos	although	this	change	does	202	
not	persist	until	7	dpf.	203	
The	GCS	 is	 also	 involved	 in	 folate	 one	 carbon	metabolism	 (FOCM)	 since	by	 degrading	204	
glycine,	gldc	donates	one	carbon	units	to	this	metabolic	cycle(7,	15,	16).	Thus,	we	examined	the	205	
levels	of	FOCM-related	metabolites	in	gldc	-/-	larvae	in	order	to	check	whether	an	imbalance	in	206	
this	 metabolism	 is	 consistently	 observed	 in	 our	 fish	 model.	 However,	 LC-MS	 titration	 of	207	
different	folate-related	metabolites	did	not	reveal	any	defect	of	the	FOCM	in	gldc	-/-	larvae	as	208	
compared	to	gldc	+/+	(Figure	4C).	We	also	noted	that	THF	makes	up	approximately	60%	of	total	209	
folate	in	zebrafish	larvae.	This	is	markedly	different	to	mammalian	(mouse	and	human)	tissue	or	210	
E.coli	in	which	5-methyl	THF	or	formyl-THF	are	abundant(15).	211	
Finally,	we	 also	 investigated	 the	 levels	 of	 lactate,	 since	 lactic	 acidosis	 is	 common	 in	 a	212	
number	 of	 metabolic	 inborn	 errors	 and	 has	 been	 reported	 in	 patients	 with	 GE	 (17-19).	We	213	
found	 that	 the	 levels	 of	 lactate	 in	 gldc	 -/-	 	 mutants	 were	 significantly	 increased	 at	 7	 dpf.	214	
Interestingly,	 there	 was	 no	 difference	 in	 the	 levels	 of	 lactate	 in	 gldc	 -/-	 and	 +/+	 at	 2	 dpf,	215	
suggesting	that	there	is	a	progressive	accumulation	of	 lactate	that	 leads	to	lactic	acidosis	at	7	216	
dpf,	whereas	the	levels	of	glycine	are	already	increased	at	2	dpf	in	gldc	-/-	(Figure	3D).	217	
Altogether,	 these	 results	 demonstrate	 that	 gldc	 loss-of-function	 induces	 previously	218	
unknown	broad	metabolic	perturbations.		219	
	220	
Transcriptomics	analysis	reveals	differences	in	the	expression	of	cell	cycle,	proliferation,	and	221	
metabolism-related	genes	in	the	gldc	-/-	mutants	222	
	 In	 the	 continuity	 of	 the	 unbiased	 metabolomics	 analysis	 in	 the	 gldc	 -/-	 mutants,	 we	223	
carried	out	a	whole	transcriptome	analysis	by	deep-sequencing	of	RNAs	extracted	from	7	dpf	224	
gldc	-/-	and	+/+	larvae.	There	were	408	differentially	expressed	genes	in	gldc	-/-	versus	gldc	+/+	225	
larvae,	of	which	153	were	up-	and	255	were	downregulated	(Figure	5A).	Using	gene	clustering	226	
and	pathway	 analysis	 from	 the	 list	 of	 significant	 differentially	 expressed	 genes,	we	 identified	227	
multiple	pathways	whose	gene	expression	was	affected.	As	expected,	multiple	genes	involved	228	
in	 general	 metabolism	 are	 mis-regulated	 in	 gldc	 -/-	 larvae.	 As	 an	 example,	 the	 amino	 acid	229	
transporter	slc6a19	was	downregulated	 in	gldc	 -/-	 (FC:	 -2.14,	p=3.61E-16,	and	 its	mutation	 in	230	
human	 causes	 a	metabolic	 disorder	 of	 neutral	 amino	 acid	 transport,	Hartnup	disease	 (Figure	231	
5B)	 (20).	 Unexpectedly,	 only	 few	 brain-specific	 genes	 were	 found	 differentially	 expressed.	232	
However,	one	of	them,	glycine	transporter	1	(slc6a9),	was	down-regulated	(FC:	-1.61,	p=1.65E-233	
08)	in	gldc-/-	compared	to	+/+,	and	is	relevant	in	the	context	of	a	neurological	disorder	like	GE.		234	
In	addition,	genes	involved	in	cell	adhesion	and	the	extracellular	matrix	(ECM),	such	as	235	
integrin	 beta	 4	 (FC:	 -1.5,	 p=6.18E-05)	 and	 laminin	 3	 (FC:	 -1.7,	 p=1.29E-05),	 were	 found	236	
downregulated	 in	gldc	 -/-	mutants.	More	 interestingly,	many	 genes	 involved	 in	 the	 cell	 cycle	237	
(e.g.	gadd45ba;	FC:	1.72,	p=3.39E-07,	as	well	as	known	oncogenes	(e.g.	c-fos	and	myc-b;	FC:	1.9,	238	
p=1.89E-07	and	FC:	1.55,	p=1.03E-07)	and	tumor	suppressor	genes	(bcl6a;	-	FC:	1.45,	p=1.03E-239	
07)	were	mis-regulated	in	gldc	-/-	compared	to	gldc	+/+	larvae.		240	
Altogether,	 these	 transcriptomic	 data	 suggest	 that	 the	 majority	 of	 genes	 whose	241	
expression	 is	affected	by	GLDC-KO	are	related	to	metabolism	and	that,	 surprisingly,	no	major	242	
transcriptomic	 changes	 occur	 in	 the	 CNS.	 Moreover,	 these	 data	 pointed	 out	 that	 cell-cycle	243	
homeostasis	 may	 be	 perturbed	 in	 gldc	 -/-	 larvae	 suggesting	 that	 cell	 proliferation	 may	 be	244	
affected	in	gldc	-/-	mutants.	245	
	246	
The	 main	 brain	 networks	 are	 not	 affected	 by	 gldc-KO	 despite	 a	 transient	 decrease	 of	247	
proliferation	in	gldc	-/-	brain		248	
The	 imbalance	 in	 the	 expression	 of	 proliferation-related	 genes	 observed	 in	 gldc	 -/-	249	
mutants	 from	 the	 RNAseq	 analysis	 led	 us	 to	 investigate	 the	 proliferation	 homeostasis	 in	 the	250	
brain	throughout	neurodevelopment.	Moreover,	a	decreased	proliferation	at	embryonic	stages	251	
has	 been	 reported	 in	 a	 mouse	 model	 of	 GLDC-KO	 (7).	 Thus,	 we	 performed	252	
immunohistochemistry	 (IHC)	at	different	developmental	 time	points	 (1,	3	and	7	dpf)	using	an	253	
antibody	 against	 the	 phosphorylated	 form	 of	 Histone	 3	 (pH3),	which	marks	 cells	 undergoing	254	
mitosis.	 Interestingly,	 this	assay	 revealed	a	 significant	decrease	 in	 cellular	proliferation	 in	 the	255	
brain	 of	gldc	 -/-	mutants	 at	 1	 and	 3	 dpf	 (Figure	 6A	 and	 6I).	 However,	 this	 slight	 decrease	 in	256	
proliferation	 does	 not	 sustain	 until	 later	 stages,	 since	 no	 difference	 is	 observed	 at	 7	 dpf	257	
between	gldc	-/-	and	+/+	larvae	(Figure	6I).		258	
Since	a	difference	in	proliferation	homeostasis	at	early	stages	of	neurodevelopment	may	259	
have	 an	 impact	 on	 the	 content	 of	 specific	 neural	 cell	 populations,	 we	 sought	 to	 investigate	260	
whether	 the	 major	 cell	 populations	 and/or	 structures	 of	 the	 brain	 neuronal	 networks	 were	261	
affected.	First,	we	checked	the	general	morphology	of	neuronal	 fibers	 in	 the	brain	of	gldc	 -/-	262	
larvae	compared	to	their	siblings	by	immunolabelling	acetylated	tubulin	(ac-Tub).	No	difference	263	
in	 the	 labeling	of	axonal	 tracks	 in	 the	brain	of	gldc	 -/-	and	+/+	was	observable	at	24	hpf,	nor	264	
later	stages	(4	dpf)	(Figure	6B).	Then,	we	aimed	at	checking	the	structure	and	neural	content	of	265	
(i)	 the	 GABAergic	 network	 using	 the	 [dlx5-6:GFP]	 transgenic	 line	 (Figure	 6C)	 (21),	 (ii)	266	
glutamatergic	network	using	the	[vglut:RFP]	transgenic	line	(Figure	6D)	(22),	(iii)	the	dopamine	267	
network	through	immunolabelling	against	tyrosine	hydroxylase	(TH)	(Figure	6E),	as	well	as	(iv)	268	
the	cerebellum	through	immunolabelling	against	paravalbumin	7	(PAV7,	labeling	Purkinje	cells)	269	
and	vglut1	(labeling	granule	cells)	(Figure	6F	and	6G).	When	comparing	the	cell	content	and/or	270	
immunolabeled	morphology	 of	 these	 neuronal	 networks	 at	 different	 time	 points	 (3,	 5	 and	 7	271	
dpf),	 we	 were	 unable	 to	 observe	 any	 differences	 in	 any	 of	 these	 brain	 network	 markers	272	
between	gldc	-/-	to	+/+	brains.	Finally,	we	also	examined	the	branchiomotor	neuron	population	273	
using	the	[islet1:GFP]	transgenic	line	as	it	is	a	sensitive	measure	of	neural	tube	anormalities	and	274	
found	no	aberrant	development	or	migration	of	the	trigeminal,	facial	and	vagal	motorneurons	275	
at	3	dpf	gldc	-/-	mutants	(Figure	6H)	(22).	These	results	indicate	that	the	transient	proliferation	276	
deficit	observed	at	3	dpf	 in	gldc	-/-	does	not	 lead	to	any	major	morphological	defect	 in	other	277	
brain	networks.	Thus,	it	is	likely	to	solely	reflect	a	transient	difference	in	the	proliferating	rate	278	
of	neural	progenitors	that	has	no	aftermath	on	brain	neural	content	and	therefore	no	specific	279	
relevance	to	the	motor	phenotype.		280	
	281	
Genetically	 and	 pharmacologically	 counteracting	 the	 exacerbated	 hyperglycinemia	 at	 the	282	
synapse	rescues	the	motor	phenotype	of	gldc	-/-		283	
Since	 our	 previous	 results	 suggest	 that	GLDC-KO	 is	 not	 affecting	 neural	 networks,	we	284	
hypothesized	 that	gldc	 -/-	 phenotype	may	 be	mainly	 due	 to	metabolic	 defects,	 as	 described	285	
above.	As	a	neurotransmitter,	glycine	is	involved	in	synaptic	signaling	through	binding	to	glycine	286	
receptors	 at	 inhibitory	 synapses	 and	 to	 NMDA	 receptors	 at	 excitatory	 synapses.	 Thus,	 we	287	
wondered	 whether	 the	 hyperglycinemia	 observed	 in	 gldc	 -/-	 larvae	 was	 affecting	 both	288	
inhibitory	and	excitatory	synaptic	 transmission.	To	 test	 this,	we	performed	a	pharmacological	289	
assay	treating	gldc	embryos	with	either	a	glycine	receptor	antagonist	(strychnine)	or	an	NMDA	290	
receptor	antagonist	(dextromethorphan).	Overnight	treatment	with	a	low	dose	of	strychnine,	a	291	
dose	not	affecting	WT	larval	behavior,	rescued	significantly	the	hypotonic	swimming	phenotype	292	
of	7	dpf	gldc	-/-	larvae	(Figure	7A).	Moreover,	acute	treatment	with	dextromethorphan	did	not	293	
significantly	 rescue	 the	 early	 motor	 deficiency	 of	 gldc	 -/-	 embryos	 at	 21	 hpf,	 but	 a	 daily	294	
exposure	rescue	the	swimming	defect	at	7	dpf	(Figure	7B	and	C).	These	results	show	that	the	295	
hyperglycinemia	 is	 indeed	 over-activating	 both	 glycine	 receptors	 and	 NMDA	 receptors	296	
throughout	the	brain,	which	contribute	to	the	GE-related	hypotonic	motor	phenotype.		297	
Then,	 we	 hypothesized	 that	 diminishing	 the	 hyperglycinemia	 at	 the	 synapse	 by	298	
overexpressing	GlyT1	(a	glycine	transporter	clearing	glycine	from	the	synaptic	cleft)	 in	gldc	-/-	299	
embryos	may	improve	their	motor	deficits.	To	test	this	assumption,	we	cloned	the	GlyT1	cDNA	300	
and	in	vitro	synthesized	its	mRNA	in	order	to	inject	it	in	the	first	cell	of	gldc	zebrafish	embryos.	301	
We	co-injected	 it	with	a	GFP-encoding	mRNA	(as	a	positive	readout)	to	allow	us	to	select	the	302	
GFP-positive	 embryo	 that	 overexpress	 GlyT1	 ubiquitously	 in	 the	 embryo	 for	 up	 to	 48	 hpf.	303	
Interestingly,	 overexpression	 of	GlyT1	 in	gldc	 -/-	 embryo	was	 sufficient	 to	 completely	 rescue	304	
their	early	motor	defect	back	to	the	level	of	their	siblings	(Figure	2D).		305	
Altogether,	these	results	confirm	that	the	hyperglycinemia	of	gldc	-/-	larvae	is	affecting	306	
normal	 glycinergic	 and	 NMDA	 signaling.	 Remarkably,	 counterbalancing	 this	 local	307	
hyperglycinemia	 at	 the	 synapse	 through	 the	 overexpression	 of	GlyT1	 completely	 rescues	 the	308	
motor	phenotype	of	gldc	-/-	embryos	(Figure	7E).	309	
	310	
Discussion	311	
In	 this	 work,	 we	 described	 two	 new	 cases	 of	 severe	 and	 mild	 GE	 and	 generated	 a	312	
zebrafish	model	of	GE	by	knocking-out	gldc	using	CRISPR/CAS9,	with	the	goal	of	characterizing	313	
the	 molecular	 mechanisms	 underlying	 GE.	 After	 showing	 the	 reminiscence	 of	 the	 gldc-/-	314	
phenotype	with	 the	symptoms	of	 severe	GE	patients,	we	sought	 for	unbiased	changes	 in	 the	315	
metabolome	 and	 transcriptome,	 and	 our	 analysis	 revealed	 unexpected	 imbalances	 in	 the	316	
metabolism	of	amino	acids	and	neurotransmitters	other	than	glycine.	Moreover,	we	found	that	317	
gldc	 -/-mutants	 display	 lactic	 acidosis	 preceding	 their	 death.	 They	 do	 not	 show	 obvious	318	
abnormalities	in	the	folate	profile.	Given	the	cell-type	specific	expression	of	gldc	at	the	7dpf	it	is	319	
possible	that	defect	in	1C	supply	is	subtle	in	whole	embryo	samples.	A	key	output	of	FOCM	is	320	
nucleotide	biosynthesis	and	we	find	cell	 that	proliferation	 in	the	brain	 is	slowed	down	during	321	
development,	leading	to	a	transient	decrease	in	the	number	of	dividing	cells	at	1	and	3	dpf.	This	322	
is	consistent	with	finding	of	diminished	cell	prolliferation	in	the	neuroepithelium	of	Gldc	mutant	323	
embryos	in	mouse(7).	However,	this	is	not	associated	with	any	gross	morphological	anomaly	in	324	
the	 main	 brain	 structures	 or	 neuronal	 networks	 of	 gldc	 -/-,	 suggesting	 that	 this	 transient	325	
reduction	of	proliferation	may	be	the	consequence	of	metabolic	perturbation,	without	having	326	
direct	consequences	on	the	motor	phenotype.	Finally,	we	confirmed	that	the	hypotonic	motor	327	
phenotype	 of	 gldc	 -/-	 mutants	 is	 mainly	 due	 to	 the	 overactivation	 of	 NMDA	 and	 glycine	328	
receptors	by	glycine	at	the	synapse.	Very	interestingly,	we	showed	that	this	hyperglycinemia	at	329	
the	synapse	can	be	recovered	by	pharmacologically	antagonizing	these	receptors,	as	well	as	by	330	
genetically	increasing	the	expression	of	glycine	transporter	1.		331	
Interestingly,	our	 findings	suggest	 that	 there	 is	an	exacerbated	hyperglycinemia	at	 the	332	
synapse	of	gldc	-/-	mutants.	Indeed,	rather	than	compensating	for	the	excess	of	glycine	at	the	333	
synapse,	we	found	that	some	of	the	metabolic	and	transcriptomic	changes	induced	by	GLDC-KO	334	
could	worsen	the	level	of	glycine	in	the	synaptic	cleft.	 In	fact,	GlyT1	expression	is	significantly	335	
decreased	in	gldc	-/-	compared	to	their	siblings,	suggesting	that	the	clearance	of	glycine	from	336	
the	cleft	may	be	slowed.	Moreover,	our	metabolomics	analysis	revealed	a	significant	increase	of	337	
sarcosine	in	gldc	-/-	 larvae,	a	non-proteogenic	amino	acid	known	to	be	a	potent	antagonist	of	338	
GlyT1	activity.	Indeed,	sarcosine	has	raised	a	significant	therapeutic	interest	in	the	recent	years	339	
as	 a	 potential	 treatment	 for	 schizophrenia	 by	 increasing	 glycinergic	 response	 in	 the	 brain	 of	340	
patients	(23).	Moreover,	the	level	of	sarcosine	is	already	significantly	elevated	at	2	dpf	in	gldc-/-	341	
embryo	suggesting	that	this	increase	may	be	the	result	of	a	more	direct	effect	of	GLDC	loss-of-342	
function	 than	 the	 other	 changes	 in	 amino	 acid	 level	 that	 are	 accumulating	 over	 time.	 As	 a	343	
result,	dampening	the	increase	in	the	level	of	sarcosine	from	early	stages	may	be	an	interesting	344	
experiment	 to	 test	 the	 relevance	 to	 target	 sarcosine	 therapeutically.	Altogether,	 our	 findings	345	
highlight	 the	 fact	 that	 the	 elevated	 glycine	 level	 at	 the	 synapse	may	 not	 be	 solely	 due	 to	 a	346	
defect	of	glycine	degradation,	but	also	to	other	synergic	changes	that	may	be	good	candidates	347	
as	therapeutic	targets	(Figure	7E).	348	
Consistent	with	the	excess	of	glycine	at	the	synapse,	we	showed	that	the	overexpression	349	
of	 GlyT1	 in	 the	 embryo	was	 sufficient	 to	 fully	 rescue	 their	motor	 condition.	 This	 is	 of	 prime	350	
interest	 for	 further	 therapeutic	 strategies	 targeting	 GlyT1	 activity.	 A	 significant	 interest	 has	351	
been	 raised	 to	 develop	 potent	 antagonists	 of	 glycine	 transporters	 for	 the	 treatment	 of	352	
schizophrenia,	 increasing	 glycinergic	 synaptic	 signaling	 (23).	 In	 contrast,	 our	 results	 strongly	353	
suggest	that	an	agonistic	action	on	GlyT1	could	be	a	key	component	for	GE	treatment.	Here	we	354	
propose	 that	 agonizing	 GlyT1	 activity	 may	 have	 a	 broader	 action	 in	 the	 brain	 by	355	
counterbalancing	 hyperglycinemia	 both	 at	 the	 glycinergic	 and	 glutamatergic/NMDA	 synapse.	356	
However,	the	attenuation	of	glycine	signaling	in	the	brain	can	have	important	side	effects	that	357	
have	 to	be	considered,	as	exemplified	by	 the	poisoning	effect	of	 strychnine,	a	potent	glycine	358	
receptor	antagonist	(24).	As	a	result,	such	a	therapeutic	strategy	would	require	the	design	and	359	
development	 of	 GlyT1	 agonists	 with	 varying	 potency,	 whose	 activity	 could	 be	 efficiently	360	
adjusted	to	each	GE	patients.		361	
	 At	 this	 juncture,	 our	 GLDC-KO	 zebrafish	 model	 could	 be	 of	 prime	 interest	 for	 drug-362	
screen	 purposes.	 Indeed,	we	 showed	 that	motor	 phenotypes	 relevant	 to	 the	 disease	 can	 be	363	
accurately	observed	and	quantified	as	early	as	20	hours	post	fertilization.	Moreover,	we	used	364	
an	 automated	 quantification	 of	 coiling	 behavior	 that	 would	 allow	 for	 high-throughput	365	
phenotyping.	As	a	result,	our	zebrafish	line	and	our	phenotyping	assay	could	serve	as	an	initial	366	
screening	tool	for	testing	the	effects	of	newly	designed	drugs,	such	as	GlyT1	agonists,	that	could	367	
then	 be	 tested	 in	 mammalian	 models.	 Of	 note	 that	 many	 CNS-related	 disorders	 have	 been	368	
successfully	 modeled	 in	 the	 past	 such	 as	 Amyotrophic	 Lateral	 Sclerosis	 and	 Spinal	Muscular	369	
Atrophy,	epilepsy,	and	autism	(25-29).	370	
Our	work	shed	new	light	on	another	facet	of	GE	as	our	metabolomics	analysis	unraveled	371	
unexpected	changes	 in	other	metabolites	than	glycine	 itself.	 Interestingly,	some	of	the	amino	372	
acids	that	are	 increased	 in	gldc	-/-	 larvae	(i.e.	 leucine	and	valine)	are	associated	with	another	373	
metabolic	 disease,	maple	 syrup	 urine	 disease	 (MSUD).	 In	 patients	 suffering	 from	MSUD,	 the	374	
metabolism	of	 branched-chain	 amino	 acids	 (BCAA),	 such	 as	 leucine,	 isoleucine,	 and	 valine,	 is	375	
impaired	 due	 to	 mutations	 in	 subunits	 of	 the	 branched-chain	 α-keto	 acids	 dehydrogenase	376	
(BCKD).	The	 levels	of	BCAA	are	thus	 increased	 in	 the	urine,	 leading	to	a	peculiar	maple	syrup	377	
smell.	 Remarkably,	 MSUD	 patients	 show	 some	 common	 symptoms	 to	 GE	 patients,	 such	 as	378	
hypotonia,	 seizures	 and	 the	only	 efficient	 treatment	 is	 a	BCAA-free	diet.	 In	 order	 to	 test	 the	379	
effect	of	an	excess	of	valine	or	 leucine	on	 the	motor	phenotype	of	 zebrafish,	we	 treated	WT	380	
embryos	 with	 these	 single	 amino-acids	 or	 in	 combination	 and	 found	 that	 they	 induce	 a	381	
reduction	of	the	coiling	and	swimming	activity	as	strong	as	when	treated	with	glycine	(data	not	382	
shown).	 These	 results	 therefore	 suggest	 that	 valine	 and	 leucine	 may	 play	 a	 role	 in	 GE	383	
pathogenesis.	 However,	 GE	 patients’	 blood	 and	 urine	 samples	 are	 rarely	 tested	 for	 other	384	
amino-acid	levels,	thus	limiting	our	interpretation.				385	
We	believe	these	findings	should	 instigate	more	profound	metabolic	testing	of	human	386	
patients,	such	as	dosage	of	BCAAs,	lactate	in	the	blood	and/or	urine,	and	glutamate	and	GABA	387	
in	 the	CSF.	This	could	allow	 identifying	putative	defects	 in	other	amino	acid	metabolism,	and	388	
therefore	 opening	 new	 therapeutic	 strategies	 that	may	not	 have	been	 considered,	 such	 as	 a	389	
BCAA-free	diet.	However,	the	fact	that	all	BCAAs	are	not	found	elevated	in	gldc-/-	fish	(such	as	390	
isoleucine)	suggests	that	this	effect	could	not	be	generalized	to	all	BCAAs	but	may	rely	on	more	391	
specific	 mechanisms	 targeting	 leucine	 and	 valine.	 In	 this	 regard,	 a	 potential	 molecular	 link	392	
between	GE	and	MSUD	might	involve	the	dihyrolipoamide	dehydrogenase	(DLD)	subunit,	which	393	
is	 part	 of	 both	 the	GCS	 and	 the	 BCKD	 complexes.	 In	 human,	DLD-deficiency	 leads	 to	 various	394	
symptoms,	 such	 as	 severe	 seizures	 and	 encephalopathy,	 muscle	 weakness,	 accumulation	 of	395	
pyruvate,	 lactate,	 BCAA	 and	 the	 related	 metabolites	 (30,	 31).	 Interestingly,	 we	 observed	396	
common	phenotypes	such	as	hypotonia,	increased	BCAA	(e.g.	valine,	leucine)	as	well	as	lactate	397	
in	gldc	-/-	mutants,	suggesting	that	gldc	knockout	might	affect	the	activity	of	other	metabolic	398	
complexes	and	therefore	induce	a	broad	metabolic	defect.	Our	metabolomic	assay	also	showed	399	
an	increase	of	arginine	in	gldc-/-	larvae.	It	is	worth	noting	that	as	a	precursor	of	nitric	oxide	and	400	
polyamine,	 L-arginine	 regulates	 basic	 physiological	 functions	 and	 it	 has	 been	 shown	 to	 be	 a	401	
player	in	age-related	degenerative	diseases	such	as	Alzheimer’s	disease(32).		402	
Previous	studies	from	Greene	et	al.	showed	an	imbalance	in	folate-related	metabolites	403	
in	Gldc	knock-out	mice(7,	16).	However,	we	did	not	detect	any	anomaly	in	the	levels	of	FOCM	404	
compounds	in	gldc	-/-	 	 larvae	(7).	One	possible	explanation	for	this	is	that	serine	degradation,	405	
another	source	of	one-carbon	units	to	the	FOCM,	could	compensate	for	the	loss	of	carbon-units	406	
from	glycine	degradation(33),	 in	addition,	 to	 the	possibility	 that	such	an	effect	would	be	cell-407	
type	or	stage-specific	(see	above).		Moreover,	the	proportion	of	1C	carrying	folates	was	found	408	
to	be	markedly	lower	in	fish	larvae	than	in	mammalian	tissue	(pre-	and	post-natal).	Thus,	THF	409	
represents	approximately	60%	of	total	folate,	perhaps	suggesting	a	lesser	requirement	for	1C-410	
carrying	folates	in	zebrafish	larva	than	in	mammalian	cells	and	tissues	(mouse	and	human)		or	411	
bacteria	in	which	5-methyl	THF	or	formyl-THF	are	predominant(15).	Thus,	these	results	suggest	412	
that	FOCM	disturbances	may	not	be	directly	involved	in	the	motor	dysfunction	associated	with	413	
GE,	but	rather	specifically	in	structural	malformations	such	as	neural	tube	defects.		414	
Altogether,	the	present	work	confirmed	the	central	role	played	by	the	hyperglycinemia	415	
in	motor	dysfunction	associated	with	GE,	but	also	unraveled	an	unexpected	broader	metabolic	416	
disturbance	that	could	also	be	essential	in	GE	pathogenesis.	Both	aspects	of	the	disease	should	417	
be	considered	in	the	design	of	new	therapeutic	strategies	aiming	at	saving	GE	neonates	as	well	418	
as	 ameliorating	 surviving	 GE	 patients’	 quality	 of	 life.	 Among	 these	 strategies,	 our	 findings	419	
suggest	that	the	development	of	glycine	transporter	1	agonists	would	be	a	putative	promising	420	
avenue,	as	well	as	BCAAs-free	diet.	421	
	422	
Methods	423	
	424	
Genetic	testing	and	glycine	titration	in	patients	425	
Blood	 sample	 from	 patients	 have	 been	 tested	 for	 NKH	 by	 PCR	 amplification	 and	 direct	 DNA	426	
sequencing	in	both	directions	of	the	9	exons	of		AMT	gene	and	25	exons	of	GLDC	gene	as	well	as	427	
the	 intron/exon	 borders.	 All	 the	 genetic	 testing	 have	 been	 performed	 at	 Denver	 Genetic	428	
Laboratories.	429	
	430	
Fish	Husbandry	and	fish	lines	431	
Wild-type	 zebrafish	 (Danio	 rerio)	were	 reared	 at	 28.5°C,	 kept	 under	 a	 12-hour	 dark,	 12-hour	432	
light	 cycle	 and	 staged	 as	 described	 previously	 (34).	 They	 were	 bred	 according	 to	 standard	433	
procedures	 (35).	 All	 experiments	 were	 performed	 in	 compliance	 with	 the	 guidelines	 of	 the	434	
Canadian	Council	 for	Animal	Care	and	conducted	at	 the	Research	Center	of	 the	University	of	435	
Montreal	 Hospital	 Center	 (CRCHUM).	 The	 dlx5-6:GFP,	 islet1:GFP	 and	 vglut2a:RFP	 transgenic	436	
lines	are	gifts	from	Marc	Ekker	and	Shin-ichi	Higashijima	respectively	(21,	36).	437	
	438	
Whole	mount	in	situ	hybridization	and	probe	cloning	439	
A	Specific	gldc	probe	corresponding	to	the	5’	part	of	the	coding	sequence	and	first	exon	(951bp	440	
amplified	 with	 the	 following	 primers:	 Forward-gaaggacctttgtgagattacgg;	 Reverse-	441	
taatgcaggccagtgagtgag)	 was	 cloned	 within	 the	 pCS2+	 vector	 using	 TOPO	 TA	 cloning	 kit	442	
(Invitrogen).	 Whole-mount	 in	 situ	 hybridization	 of	 zebrafish	 embryos	 was	 performed	 as	443	
described	by	(37).		444	
	445	
sgRNA	and	cas9	preparation	and	microinjection	446	
The	following	gRNA	sequence	targeting	the	fourth	exon	of	the	gldc	gene	was	designed	using	the	447	
online	tool	CRISPRscan	((PAM	site	is	indicated	in	brackets):	gggacacctcgggctggta(cgg).	Synthesis	448	
of	 gRNA	 and	 Cas9	 mRNA	 was	 performed	 as	 described	 by	 (12).	 Wild-type	 embryos	 were	449	
collected	 for	microinjection.	A	1nL	drop	of	a	mix	of	100	ng/μL	of	Cas9	mRNA	and	30	ng/L	of	450	
gRNA	was	injected	into	one-cell	stage	embryos.	451	
	452	
High-resolution	melting	(HRM)	453	
Primers	were	designed	using	the	Universal	Probe	Library	Assay	Design	Center	(Roche).	Forward:	454	
TTCAGTGAGTATTTGTGTTCTCTACAGG;	 Reverse:	 TGGTCTGATAGTTGAGTAAGCTCTCC.	 The	 PCR	455	
reactions	was	performed	as	described	by	(12).	456	
	457	
Coiling	analysis	and	swim	tracking	458	
20hpf	 embryos	 were	 embedded	 in	 low	 melting	 agarose	 and	 covered	 with	 water,	 their	459	
movements	inside	the	chorion	were	recorded	using	a	camera	for	20	minutes.	The	Danioscope	460	
software	(Noldus)	was	then	used	to	quantify	the	number	of	bursts	over	time.	At	7	dpf,	 larvae	461	
were	transferred	individually	into	a	96-well	plate	and	swim	distance	was	recorded	using	Basler	462	
GenIcam	camera	and	DanioVision	 recording	 chamber	 (Noldus).	Analysis	was	performed	using	463	
the	Ethovision	XT	12	software	(Noldus)	to	quantify	the	distance	swam.	464	
	465	
Hypotonia	and	swim	balance	tests	466	
One	gldc	-/-	mutant	and	one	sibling	7	dpf	larva	were	placed	in	the	center	of	a	water-filled	petri	467	
dish	 and	 a	water	 current	was	manually	 applied.	 For	 the	 swimming	 balance	 test,	 a	 heat	map	468	
tracking	 the	movement	 of	 the	 larvae	 using	 the	Noldus	Danio	 Vision	 software	was	 generated	469	
over	10	minutes.		470	
	471	
Mass	spectrometry	liquid	chromatography		472	
Analysis	 of	 multiple	 folates	 was	 performed	 by	 UPLC-MS/MS	 as	 described	 previously	 (16).		473	
Amino	 acids	 were	 detected	 and	 quantified	 by	 LC-MS/MS	 as	 previously	 described	 (38,	 39).	474	
Processing	of	the	chromatograms	obtained	by	LC-MSMS	was	done	using	TargetLynx	(Waters),	475	
including	peak	detection,	peak	 integration	and	concentration	estimation	based	on	calibration	476	
curves.	For	statistical	analyses,	Student’s	T-test	was	used.	Significance	testing	and	graphing	was	477	
performed	with	GraphPad	Prism	7	software.	Analysis	of	the	neurotransmitter	and	lactate	was	478	
performed	as	described	by	(40).	The	extraction	details	are	available	upon	request.	479	
	480	
Transcriptomic	assay,	differential	expression	assay	and	pathway	analysis	481	
Total	RNA	was	extracted	from	7	dpf	gldc	-/-	and	+/+	 larvae	using	picopure	RNA	extraction	kit	482	
(Thermo	Fisher	Scientific)	following	the	manufacturer’s	standard	protocol.	Quality	of	total	RNA	483	
was	assessed	with	the	BioAnalyzer	Nano	(Agilent)	and	all	samples	had	a	RIN	above	9.		484	
Library	preparation	was	done	as	described	by	(41).	Sequencing	was	performed	with	the	Illumina	485	
NextSeq500	using	 the	SBS	Reagent	Kit	v3	 (100	cycles,	paired-end)	with	1.6	nM	of	 the	pooled	486	
library.	Cluster	density	was	targeted	at	around	800k	clusters/mm2.	Between	73	and	98	million	487	
reads	were	 generated	 for	 each	 sample.	 Library	 preparation	 and	 sequencing	was	 done	 at	 the	488	
Institute	 for	 Research	 in	 Immunology	 and	 Cancer’s	 Platform	 (University	 of	Montreal).	 About	489	
95%	 of	 high	 quality	 reads	 were	 mapped	 onto	 the	 zv9	 version	 of	 the	 zebrafish	 genome	490	
(ensemble	release	77)	using	TopHat	version	2.0.10.		491	
Differential	 gene	 expression	 analysis	 was	 assessed	 by	 DeSeq2	 package	 using	 R	 software.	492	
Differential	gene	expression	was	filtered	on	a	False	Discovery	Rate	(or	adjusted	p	value	>	0.05).	493	
Pathway	 analysis	 was	 performed	 using	 DAVID	 bioinformatics	 resources	 (42).	 The	 list	 of	494	
differentially	 expressed	 genes	 was	 uploaded	 onto	 DAVID	 analysis	 wizard	 and	 a	 list	 of	 all	495	
expressed	genes	found	in	our	dataset	was	used	as	a	background	for	gene	enrichment	analysis.		496	
	497	
Immunohistochemistry	and	pH3	and	pav7	quantification	498	
Gldc	 -/-	 and	 +/+	 embryos	 were	 anaesthetized	 in	 0.2%	 tricaine,	 fixed	 with	 4%	499	
paraformaldehyde	for	1h30	at	room	temperature	(or	 in	Dent’s	overnight	at	4ºC	for	pH3	 IHC).	500	
Immunohistochemistry	was	performed	as	previously	described	 (43)	with	anti	Ac-Tub	 (1:1000,	501	
T6793,	 sigma),	 anti-pH3	 (polyclonal,	 1:500,	 06-570,	 millipore),	 anti-TH	 (1:400,	 mab318,	502	
millipore),	anti	vGluT1	(1:500),	or	anti-pav7	(1:1000,	both	gifts	of	Masahiko	Hibi).	Quantification	503	
of	Pav7-	and	pH3-positive	cells	was	done	blindly	by	using	the	count	tool	on	Photoshop.		504	
	505	
Drug	treatments	506	
All	drugs	were	obtained	 through	Sigma.	The	drug	 solutions	were	prepared	as	 follows:	10mM	507	
stock	solution	of	strychnine	(S0532)	was	prepared	by	dissolving	33.4mg	of	powder	in	10mL	of	508	
water;	10mM	stock	solution	of	Dextromethorphan	(D9684)	was	prepared	by	dissolving	37mg	of	509	
powder	 in	 10mL	 of	 water.	 The	 stock	 solution	 was	 dissolved	 in	 fish	 water	 to	 reach	 the	 final	510	
concentration.	 Embryos	 and	 larvae	 were	 individualized	 in	 glass	 beaker	 in	 a	 total	 volume	 of	511	
50mL	and	were	incubated	overnight	in	a	lightproof	box	at	28.5ºC.	512	
	513	
Glycine	Transporter	1	cloning	and	mRNA	in	vitro	synthesis	514	
Full-length	 cDNA	 of	 GlyT1	 was	 cloned	 from	 24	 hpf	 total	 RNAs	 using	 the	 following	 primers:	515	
Forward	:	 ATGAACAGCAGAAAGAATGGAGCA;	 Reverse	:	 CTATGCGCTGGGTGTGGG.	 The	 PCR	516	
product	 was	 cloned	 within	 the	 pCS2+	 vector	 using	 TOPO	 TA	 cloning	 kit	 (Invitrogen).	 After	517	
sequencing,	the	corresponding	mRNA	was	transcribed	in	vitro	using	SP6	RNA	polymerase.	518	
	519	
Statistics	520	
Statistical	analysis	for	comparing	two	groups	were	performed	using	a	t-test.	When	comparing	521	
more	than	two	groups,	the	statistical	analysis	performed	corrected	for	multiple	comparisons	522	
and	also	for	repeated	measures	when	comparing	multiple	measurements	between	groups	523	
using	a	Bonferroni	correction	for	multiple	comparisons.	Raw	results	are	displayed	with	box	and	524	
whiskers	showing	the	min	and	max	values	as	well	as	the	median	value	(line).	525	
	526	
Study	approval	527	
Genetic	 testing	 were	 performed	 under	 written	 consent	 from	 the	 patients.	 All	528	
experiments	 were	 performed	 in	 compliance	 with	 the	 guidelines	 of	 the	 Canadian	 Council	 for	529	
Animal	 Care	 and	 conducted	 at	 the	 Research	 Center	 of	 the	 University	 of	 Montreal	 Hospital	530	
Center	(CRCHUM).	The	vertebrate	animal	welfare	assurance	from	the	Institutional	Animal	Care	531	
and	Use	Committee	(IACUC)	for	the	use	of	adult	zebrafish	has	been	approved	on	2015/08/31.	532	
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Figure	and	Figure	Legends	685	
	686	
Figure	1:	GLDC	mutations	associated	with	lethal	or	severe	glycine	encephalopathy.	A.	Genetic	687	
and	molecular	 testing	of	 the	patients	performed	at	 the	Denver	Genetic	Laboratories	 showing	688	
the	mutation	found	in	GLDC	as	well	as	plasma	and	cerebrospinal	fluid	(CSF)	glycine	level.	B.	The	689	
genetic	 position	 of	 each	mutation	 is	 indicated	 on	 the	 scheme	 depicting	 the	 25	 exons	 of	 the	690	
GLDC	gene.	C.	Consequences	of	the	mutations	on	the	expected	GLDC	protein	size.	691	
	692	
Figure	 2:	 Zebrafish	gldc	 is	 expressed	 in	 the	 central	 nervous	 system	 and	 its	 loss-of-function	693	
induces	glycine	accumulation.	A.	In	situ	hybridization	of	gldc	transcript	at	8,	18,	24,	32,	and	42	694	
hours	post	fertilization	(hpf)	showing	the	expression	 in	the	brain	and	spinal	cord	as	well	as	 in	695	
the	intestine	at	later	stages.	B.	CRISPR/CAS9	mutagenesis	targeting	the	4th	exon	of	gldc	 led	to	696	
substitution	 of	 2	 nucleotides	 and	 deletion	 of	 5	 nucleotides.	 These	DNA	mutations	 in	gldc	 -/-	697	
induce	a	melting	 curve	 shift	 compared	 to	+/+	 that	allows	 for	 rapid	genotyping.	C.	 Scheme	of	698	
several	 nonsense	mutations	 identified	 in	 patients	 leading	 to	 insertion	 of	 stop	 codons	 in	 the	699	
glycine	cleavage	domain	of	the	human	GLDC	protein.	In	red,	the	mutant	variant	of	the	glycine	700	
encephalopathy	patient	described	here,	and	in	red	in	the	zebrafish	GLDC	protein,	the	location	701	
of	 the	 CRISPR	 mutation.	 D.	 RT-qPCR	 analysis	 of	 the	 gldc	 mRNA	 levels,	 reveals	 a	 significant	702	
decrease	in	gldc	-/+	and	-/-	compared	to	+/+,	at	7	dpf	(ANOVA,	***:	<	0.0004;	**:	<	0.005,	n>10,	703	
N=3).	 LC-MS	 dosage	 of	 glycine	 levels	 in	 whole	 7	 days	 post	 fertilization	 larvae	 reveals	 a	704	
significant	increase	in	gldc	-/-,	but	not	-/+,	compared	to	+/+	(ANOVA,	****:	<0.0001,	n=3,	N=3).	705	
Box	 and	whiskers	 display	min	 and	max	 values	 and	 a	 line	 shows	 the	median	 value.	 Each	 dot	706	
corresponds	to	an	individual	experiment	(N)	of	at	least	5	fish	(n>5).	707	
	 	708	
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Figure	3:	Gldc	-/-	larvae	die	prematurely	and	depict	disease-reminiscent	motor	phenotypes.	A.	710	
Gldc	 -/-	 larvae	 die	 prematurely	 between	 7	 and	 9	 days	 post	 fertilization.	 B.	 The	 general	711	
morphology	 of	 the	 fish	 is	 not	 affected	 as	 shown	 by	 the	 quantification	 of	 the	 eye	 spacing	712	
distance,	eye	diameter,	and	body	 length	of	gldc	 -/-	 compared	to	+/+.	C.	Although	there	 is	no	713	
obvious	 morphological	 defect	 in	 gldc	 -/-	 at	 7	 dpf,	 -/-	 larvae	 are	 distinguishable	 from	 their	714	
siblings	 thanks	 to	 their	 hyperpigmentation.	 D.	 Hematoxylin/Eosin	 staining	 performed	 on	715	
transverse	 sections	 from	 7	 dpf	 gldc+/+	 and	 -/-	 larvae	 show	 no	 obvious	 difference	 of	 brain	716	
morphology.	 E.	 Analysis	 of	 the	 frequency	 of	 spontaneous	 coiling	 of	 the	 tail	 at	 21	 hours	 post	717	
fertilization,	 the	 earliest	 motor	 phenotype	 in	 zebrafish	 embryo,	 reveals	 a	 decrease	 of	 this	718	
behavior	in	gldc	-/-	larvae,	compared	to	+/+	(ANOVA	p=0.0002).	F.	Analysis	of	the	total	distance	719	
swam	over	1h	at	7	days	reveals	a	significant	decrease	of	swimming	in	gldc	-/-	compared	to	+/+	720	
(ANOVA	p=0.0077).	G.	Tracking	of	the	position	of	gldc	+/+	and	-/-	7	days	post-fertilization	larvae	721	
from	the	center	point	after	application	of	a	water	current	 show	a	balance	problem	of	gldc-/-	722	
larvae.	H.	Indeed,	gldc	-/-	 larvae	take	significantly	more	time	to	stabilize	their	swimming	after	723	
application	of	the	water	current	compared	to	gldc	+/+	(t-test,	p=0.0008).	I.	Heatmap	tracking	of	724	
the	swimming	zone	of	7	dpf	larvae	over	10	min	reveals	that	gldc	-/-	larvae	are	swimming	only	in	725	
the	upper	part	of	water,	whereas	gldc	+/+	swim	in	both	upper	and	lower	sections	of	the	water.	726	
J.	 Quantification	 of	 the	 time	 spent	 in	 the	 upper	 versus	 lower	 swimming	 zone	 of	 the	 water	727	
reveals	that	gldc	-/-	spend	significantly	more	time	in	the	upper	swimming	zone	compared	to	+/+	728	
(ANOVA,	p<0.0001).	Box	and	whiskers	display	min	and	max	values	and	a	line	shows	the	median	729	
value.	Each	dot	corresponds	to	an	individual	experiment	(N)	of	at	least	5	fish	(n>5).	730	
	 	731	
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Figure	4:	Metabolomics	analysis	indicates	broad	metabolic	perturbations	in	gldc	-/-	larvae.	A.	733	
LC-MS	analysis	of	the	levels	of	the	main	proteogenic	and	non-proteogenic	amino	acids	at	7	dpf	734	
reveals	 a	 significant	 increase	 in	 sarcosine,	 proline,	 glycine,	 valine,	 cysthationine,	 leucine,	 and	735	
arginine	 in	 gldc	 -/-	 compared	 to	 +/+	 (t-test,	 respectively,	 p=0.035,	 p=0.0062,	 p<0.00001,	736	
p=0.0006,	p=0.0006,	p=0.029,	and	p=0.0006).	B.	LC-MS	analysis	of	the	main	neurotransmitter	at	737	
7	dpf	reveals	a	significant	decrease	in	glutamate	and	GABA	in	gldc	-/-	compared	to	+/+	(t-test,	738	
both	p<0.00001).	C.	LC-MS	analysis	of	folate	compounds	did	not	reveal	any	difference	between	739	
gldc	 -/-	 and	+/+	 at	 7dpf.	 Box	 and	whiskers	display	min	 and	max	 values	 and	a	 line	 shows	 the	740	
median	value.	Each	dot	corresponds	to	an	individual	experiment	(N)	of	at	least	3	fish	(n>3).	741	
	 	742	
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Figure	 5:	 Transcriptomics	 analysis	 reveals	 differences	 in	 the	 expression	 of	 cell	 cycle,	744	
proliferation,	 and	 metabolism-related	 genes	 in	 the	 gldc	 -/-	 mutants.	 A.	 RNA	 sequencing	745	
analysis	 of	 7	 dpf	 larvae	 reveals	 that	 408	 genes	 are	 differentially	 expressed,	 with	 255	 up-746	
regulated	 and	 153	 downregulated,	 in	 gldc	 -/-	 compared	 to	 +/+.	 B.	 Pathway	 analysis	 of	 the	747	
differentially	 regulated	 genes	 reveals	 that	 genes	 involved	 in	 metabolism,	 cell	 cycle/growth,	748	
oncogene/proliferation	 and	 tumor	 suppressor,	 extracellular	 matrix,	 and	 one	 in	749	
neurotransmission	are	mis-regulated	in	gldc	-/-	compared	to	+/+.	750	
	 	751	
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Figure	6:	The	main	brain	networks	are	not	affected	by	gldc-KO	despite	a	transient	decrease	of	753	
proliferation	in	gldc	-/-	brain.	A.	Immunohistochemistry	against	phospho-histone	3	(Ph3)	labels	754	
proliferating	cells	on	gldc	-/-	and	+/+	3	dpf	larvae.	B.	Immunohistochemistry	against	acetylated	755	
tubulin	labelling	axonal	tracks	did	not	reveal	any	gross	morphological	difference	at	1	and	4	dpf	756	
between	 gldc	 -/-	 and	 +/+	 larvae.	 C.	 The	 transgenic	 dlx5/6:GFP	 line	 was	 used	 to	 visualize	757	
GABAergic	cells	in	gldc	-/-	and	+/+	7	dpf	larvae.	D.	Using	the	vGluT2:RFP	transgenic	line	to	label	758	
the	glutamatergic	network	did	not	reveal	any	gross	morphological	difference	between	gldc	-/-	759	
and	 +/+	 7	 dpf	 larvae.	 E.	 Immunohistochemistry	 against	 tyrosine	 hydroxylase	 labelling	760	
dopaminergic	neurons	did	not	reveal	any	gross	morphological	difference	between	gldc	-/-	and	761	
+/+	 at	 5	 dpf.	 F.	 Immunohistochemistry	 against	 paravalbumin	 7	 labels	 purkinje	 cells	 of	 the	762	
cerebellum	on	5	dpf	gldc	-/-	and	+/+	larvae.	G.	Immunohistochemistry	against	vGluT1	labelling	763	
granule	cells	of	the	cerebellum	did	not	reveal	any	gross	morphological	difference	between	5dpf	764	
gldc	 -/-	 and	 +/+	 larvae.	 H.	 Using	 the	 islet1:GFP	 transgenic	 line	 to	 label	 the	 branchiomotor	765	
neuron	network	did	not	reveal	any	gross	morphological	difference	between	gldc	-/-	and	+/+	3	766	
dpf	larvae.	I.	Quantification	of	the	number	of	Ph3	positive	cells	revealed	a	significant	decrease	767	
of	 proliferating	 cells	 in	 gldc	 -/-	 compared	 to	 +/+	 at	 1	 and	 3	 dpf,	 but	 not	 7	 dpf	 (t-test,	768	
respectively,	 p=0.0223	 and	 p=0.014).	 J.	 Quantification	 of	 the	 number	 of	 dlx5/6:GFP	 positive	769	
cells	did	not	 reveal	any	difference	between	gldc	 -/-	 and	+/+.	K.	Quantification	of	 the	number	770	
paravalbumin	7	positive	cells	did	not	reveal	any	difference	between	gldc	-/-	and	+/+.	Box	and	771	
whiskers	display	min	and	max	values	and	a	line	shows	the	median	value.	Each	dot	corresponds	772	
to	an	individual	biological	replicate	(n>5).	773	
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Figure	7:	Genetically	and	pharmacologically	 counteracting	 the	exacerbated	hyperglycinemia	776	
at	 the	 synapse	 rescues	 the	 motor	 phenotype	 of	 gldc	 -/-.	 A.	 Overnight	 treatment	 with	777	
strychnine	 5uM	 significantly	 rescues	 the	 hypotonic	 swimming	 of	 gldc	 -/-	 (n=6)	 at	 7	 days	778	
compared	 to	 vehicle	 treated	 gldc	 -/-	 (n=11)	 (p=0.0446;	 for	 vehicle	 treated	 -/-	 vs.	 sib/+,	779	
p=0.0002).	 B.	 Overnight	 treatment	 with	 dextromethorphan	 50uM	 decreases	 the	 hypotonic	780	
coiling	of	gldc	-/-	(n=23)	compared	to	vehicle	treated	gldc	-/-	embryos	(n=27)	at	21	hpf,	(vehicle-781	
treated	 sib/+	 vs.	 dextromethorphan-treated	 sib/+,	 p<0.0001;	 vehicle-treated	 sib/+	 vs.	 -/-,	782	
p=0.0013).	 C.	 Daily	 dextromethorphan	 25uM	 treatment	 over	 7	 days	 significantly	 rescues	 the	783	
hypotonic	 swimming	 of	 gldc	 -/-	 (n=4)	 at	 7	 days,	 compared	 to	 vehicle-treated	 gldc	 -/-	 larvae	784	
(n=6)	(p=0.0129;	vehicle-treated	sib/+	vs.	-/-,	p=0.0017).	D.	First-cell	stage	Glycine	Transporter	1	785	
(GlyT1)	 mRNA	 injection	 rescues	 the	 coiling	 defect	 of	 gldc-/-	 embryos	 at	 21	 hours	 post	786	
fertilization	compared	to	GFP	injected	gldc	-/-	(n>15,	N=4)	(p=0.0064;	GFP-injected	sib/+	vs.	-/-,	787	
p=0.015).	E.	Model	representation	of	NMDA	and	glycine	synapses	of	gldc	-/-	compared	to	+/+.	788	
Gldc	-/-	have	an	exacerbated	hyperglycinemia	at	these	synapses	due	to	a	decrease	in	GlyT1	and	789	
an	increase	in	the	levels	of	sarcosine.	Box	and	whiskers	display	min	and	max	values	and	a	line	790	
shows	the	median	value.	Each	dot	corresponds	to	an	individual	experiment	(N)	of	at	least	5	fish	791	
(n>5).	792	
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